Tag Archives: Adults Aged 50-59

GSK Seeks Regulatory Approval to Extend RSV Vaccination to At-Risk Adults Aged 50-59

(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release